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Abstract.  Transgenic mice were generated with a fu- 
sion gene carrying a portion of the murine myelin pro- 
teolipid protein (PLP) gene, including the first intron, 
fused to the E.  coli LacZ gene. Three transgenic lines 
were derived and all lines expressed the transgene in 
central nervous system white matter as measured by a 
histochemical assay for the detection of/~-galactosi- 
dase activity. PLP-LacZ transgene expression was 
regulated in both a  spatial and temporal manner,  con- 
sistent with endogenous PLP expression.  Moreover, 
the transgene was expressed specifically in oligoden- 
drocytes from primary mixed glial cultures prepared 
from transgenic mouse brains and appeared to be de- 
velopmentally regulated in vitro as well. Transgene 
expression occurred in embryos, presumably in pre- or 
noumyelinating cells, rather extensively throughout the 
peripheral  nervous system and within very discrete 
regions of the central nervous system. Surprisingly, 
/~-galactosidase activity was localized predominantly in 
the myelin in these transgenic animals,  suggesting that 
the NH2-terminal  13 amino acids of PLP, which were 
present in the PLP-LacZ gene product, were sufficient 
to target the protein to the myelin membrane.  Thus, 
the first half of the PLP gene contains sequences suf- 
ficient to direct both spatial and temporal gene regula- 
tion and to encode amino acids important  in targeting 
the protein to the myelin membrane. 
M 
YELIN  is  a  highly  specialized  extension  of the 
plasma membrane elaborated by oligodendrocytes 
in  the  central  nervous  system  (CNS)  1 and  by 
Schwann cells in the peripheral nervous system (PNS). My- 
elin ensheathes a segment of an axon, forming a tightly com- 
pacted multilamellar  structure (Raine,  1984),  which func- 
tions to promote saltatory conduction of the nerve impulse 
(Huxley and Staemptti,  1949).  Myelination  is essential  for 
nervous system function, with dysmyelination  resulting  in 
devastating forms of mental retardation.  In addition,  demye- 
lination in the adult, such as in multiple sclerosis in humans, 
results in serious motor and sensory disorders.  Myelination 
involves the coordinate expression of a small set of myelin- 
specific genes (for review see Campagnoni,  1988; Campa- 
gnoni and Macklin,  1988; Ikenaka et al.,  1991; Mikoshiba 
et al.,  1991). One of these genes,  the proteolipid protein 
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(PLP) gene provides an excellent model to study gene regu- 
lation for many reasons.  (a) The PLP gene is abundantly  ex- 
pressed. Its gene products constitute roughly 50 % of the to- 
tal protein found in adult CNS myelin  (Eng et al.,  1968; 
Norton and Poduslo,  1973).  (b) Its expression is cell-type 
specific,  primarily  restricted to oligodendrocytes.  (c) The 
gene is regulated developmentally with peak expression oc- 
curring during the early postnatal period in rodents. (d) PLP 
gene expression can be studied in vitro in primary cultured 
oligodendrocytes  in  the  absence  of  any  neural  signals 
(Dubois-Dalcq et al., 1986).  (e) Mutations in this gene are 
devastating,  and animals  such as the jimpy mouse or the 
myelin-deficient rat are severely compromised, dying within 
the first two months after birth. (f) The PLP gene products 
are targeted specifically  to the myelin membrane. 
The PLP gene is present as a single copy in the genome 
(Milner et al.,  1985;  Diehl et al.,  1986; Gardinier  et al., 
1986) located on the X chromosome (Willard and Riordan, 
1985; Mattei et al., 1986). The general gene structure in the 
mouse (Macklin et al.,  1987, 1991; Ikenaka,  1988) and hu- 
man (Diehl et al.,  1986) is quite similar;  roughly 17 kb of 
DNA encompass seven exons with a large first intron  (7-8 
kb). The coding  sequence of the PLP gene is highly  con- 
served with 100% identity among the mouse, rat, and human 
sequences at the amino acid level and >95 % identity  at the 
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servation for the 5'-and 3'-untranslated regions of the gene, 
even extending into the 5'-flanking DNA (Macklin et al., 
1987). 
Two protein products are generated from the PLP gene, 
by use of an alternative splice site within exon 3; PLP which 
contains 276  amino acids and a  related protein,  DM-20, 
which does not contain PLP residues 116-150  (Macklin et 
al.,  1987; Nave et al.,  1987; Simons et al.,  1987).  DM-20 
protein is expressed prior to PLP during development but as 
development proceeds, PLP becomes the predominant pro- 
tein (Kronquist et al.,  1987; Gardinier and Macklin, 1988; 
LeVine et al.,  1990;  Schindler et al.,  1990).  Likewise, the 
transcripts encoding both proteins are temporally regulated 
(LeVine et al., 1990) with the expression of DM-20 mRNA 
preceding that of PLP mRNA and occurring embryonically 
in the mouse (Pham-Dinla et al., 1991; Ikenaka et al., 1992; 
Timsit et al.,  1992a).  Although PLP expression has been 
demonstrated in Schwann cells, it may not be incorporated 
into myelin sheaths (Puckett et al.,  1987; Kamholz et al., 
1992).  Unlike the developmental switch observed in oligo- 
dendrocytes, both DM-20 mRNA and protein expression are 
higher than PLP mRNA and protein in rat sciatic nerve at 
postnatal day 14 (Pham-Dinh et al.,  1991). 
The transcriptional regulatory elements controlling PLP 
gene expression have been difficult  to map in vitro, primarily 
due to a paucity of PLP-expressing cell lines. Several recent 
studies have used deletion-transfection analysis to localize 
transcriptional regulatory elements within the PLP gene. 
While these studies identified elements that modulate PLP 
gene expression in both a positive and negative fashion, none 
of these elements were sufficient to direct tissue-specific ex- 
pression of the  PLP gene entirely.  In these experiments, 
0.3-5.0 kb of Y-flanking DNA of the PLP gene was used to 
drive reporter gene expression. The results indicate that the 
PLP promoter can be transcribed in a number of cell types, 
including many cells that do not express the PLP gene nor- 
maUy. Mouse PLP-luciferase chimeric genes had significant 
transcriptional activity in either hamster glial cells or mouse 
hepatoma cells (Cook et al., 1992).  Likewise, fusion genes 
containing rat  Y-flanking PLP DNA  promoted chloram- 
phenicol acetyl transferase (CAT) expression in both glial 
and nonglial cells (Nave and Lemke, 1991). In contrast, hu- 
man PLP sequences directed high level CAT expression in 
human astroglial cells but not in nonglial cells (Berndt et al., 
1992),  suggesting that this construct might contain some 
tissue-specific elements, although it is unclear why astroglial 
cells should express the reporter gene, since they do not ex- 
press PLP. Taken together, these studies suggest that the 5'- 
flanking DNA of the PLP promoter can direct gene expres- 
sion in many cells, while sequences important to restricting 
tissue-specific expression of the PLP gene may reside else- 
where in the gene. Since the structure of the PLP gene is 
highly conserved and the first intron accounts for almost half 
of the gene, we hypothesized that a tissue specific element(s) 
might reside within intron 1. To test this, transgenic animals 
were generated using a PLP-LacZ fusion gene which con- 
tained intron 1 and coded for the first 13 amino acids of PLP. 
Three transgenlc lines were derived and all lines expressed 
the  transgene  (/~-galactosidase)  both  spatially  and  tem- 
porally consistent with endogenous PLP expression. Trans- 
gene expression was maintained in primary cultured oligo- 
dendrocytes thus effectively  tagging these cells for future use 
in transplantation studies.  Surprisingly, a  greater level of 
transgene expression was observed in the embryonic PNS as 
opposed to the CNS. In adult animals, B-galactosidase activ- 
ity was present in the myelin, suggesting that the first 13 
amino acids were sufficient to target the protein appropri- 
ately. Thus, these transgenic animals provide an extremely 
potent model to study gene regulation in the developing ner- 
vous system. 
Materials and Methods 
Transgenic Plasmid Construction 
A KpnI-ApaI  fragment encompassing the latter two thirds of PLP intron 
1 and the first part of exon 2 was isolated from genomic lambda clone 9a 
(Macklin et al.,  1987). The ApaI  site was converted to a SpH site by 
removal of the Y-overhang with  T4  DNA polymerase  and  the subse- 
quent ligation of a  SphI synthetic linker  (5"GC~ATGCC-3';  Promega, 
Madison,  WI).  The KpnI-SphI fragment  was subcloned into the corre- 
sponding  sites  in pGEM-7Zf(-) (Promega)  and the resulting  plasmid 
was designated KS-5.5. A ClaI-KpnI fragment from lambda KK1 (Macklin 
et al.,  1991) containing PLP 5"flanking DNA, all of exon 1 and the first 
third of intron 1 was inserted upstream of PLP sequences in KS-5.5 at the 
ClaI and KpnI sites,  thus regenerating PLP intron  1.  This plasmid was 
termed CS(+). A LacZ expression cassette containing the HindIII-BamHI 
fragment from plasmid pCHll0 (Pharma¢ia Biotech Inc., Piscataway, NJ) 
was subcloned into pBluescript KS(+) (Stratngene, La Jolla, CA) and desig- 
nated pGAL5 (gift of N.  Mori  and D. Anderson,  California Institute of 
Technology, Pasadena, CA). The HindllI site was converted to a SphI site 
by a fill-in reaction with DNA polymerase I large fragment and four dNTPs 
followed  by the addition ofa Sphl linker, generating plasmid pGALSph. The 
ApaI-SphI PLP fragment from CS(+) was llgated into the ApaI and Sphl 
sites of pGALSph generating plasmid AS(+)GAL.  To remove an in-frame 
stop codon downstream from the PLP initiating methionine, pGAL5 was 
digested with KpnI to delete a 239-bp fragment and the remaining KpnI site 
was converted to a SphI site as described above, yielding plasmid pGALAK. 
The final construct was designated PLP(+)Z and it was generated by replac- 
ing the LacZ expression cassette (SphI-NotI fragment) in AS(+)GAL with 
the analogous Sphl-NotI fragment  from pGALAK which essentially re- 
moved the in-frame  stop codon.  Thus  PLP(+)Z contains  2.4 kb of 5'- 
flanking PLP DNA, all of exon 1 and intron 1, and the first 37 bp of PLP 
exon 2 ligated to a trpS-LacZ fusion gene and SV-40 polyadenylation sig- 
nals (nucleotides 209-3736  of pCH110). 
Production of Transgenic Mice 
PLP(+)Z was digested with ApaI and NotI and fractionated on a 0.7% 
agarose gel. A 14-kb band of DNA was excised from the gel and electro- 
eluted. The DNA was subjected to several extractions with phenol/chloro- 
form and then precipitated twice with 3 M sodium acetate and ethanol. The 
precipitate was redissolved in TE (10 mM Tris, 1 mM EDTA) at a concen- 
tration of '~ 200 copies/pl. Transgenic animals were generated by the injec- 
tion of DNA into pronuclei of BDF2-fertilized mouse eggs (Hogan et al., 
1986; Readhead et al., 1987). Fertilized eggs were incubated overnight in 
M16 media (Hogan et al., 1986) in a 5% CO2 incubator at 37°C, and the 
next day, 15 to 20 two-cell stage embryos were transferred into the left 
oviduct of  BDF1 pseudopregnant mouse. The mice were allowed to develop 
to term. At 3 wk of  age, the animals were weaned and screened for transgene 
integration. 
Screening  for Potential Transgenic Founders 
A piece of tail was biopsied from potential founder mice under anesthesia. 
DNA was isolated  from tail  biopsies by incubation overnight with pro- 
teinase K (100 #g/ml) in 50 mM Tris,  100 mM EDTA, at 50°C followed 
by one extraction with phenol, two extractions with phenol/chloroform (1:1) 
and a final extraction with chloroform alone. The DNA was precipitated 
with 3 M sodium acetate and ethanol. The DNA was resuspended with TE. 
The transgene was identified by Southern blot analysis. Genomic DNA (10 
~g) was digested with BamHI, electrophoresed on 0.7 % agarose gels, and 
transferred to nitrocellulose. The blots were hybridized to random primed 
LacZ sequences (SphI-NotI  fragment from pOALAK). 
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B-galactosidase-expressing cells were identified in mice by staining with 
X-gal (5-bromo-4-chloro-3-indolyl-B-galactopyranoside;  Promega) as de- 
scribed by Sanes et al.  (1986) or with Bluo-gal (halogenated indolyl-/3- 
v-galactoside; GIBCO BRL Life Technologies, Inc., Gaithersburg, MD) as 
described  by l.x~wy et al.  0991).  Briefly, mice were anesthetized  with 
halothane  and  perfused  intracardially  with  PBS  followed  by  0.5% 
paraformaldehydeq.0%  glntaraldehyde in PBS, pH 7.3, and finally in the 
same  fixative containing  10%  sucrose.  Perfnsed  animals  were  left un- 
disturbed for 1 h after which tissues were dissected out and immersed in 
the fixative containing 10% sucrose. Upon dropping, tissue sank in the same 
fixative containing 25% sucrose (usually overnight at 40C), and was stored 
at -80"C until cryostat sectioning (20-30 ttm). The X-gal stain consisted 
of 1 mg/ml X-gal, 5 mM potassium  ferrieyanide, 5 mM potassium  fer- 
roeyanide, 2 mM MgC12, 0.02% NP-40, and 0.01% sodium deoxycholate in 
PBS. The Bluo-gal stain consisted of 2 mM Bluo-gal,  16 mM potassium 
ferricyanide,  16 mM potassium  ferrocyanide, and 2 mM MgC12 in PBS. 
Stains were filtered with 0.45/~m membranes and incubated with tissue sec- 
tions for 14-18 h at 37°C. Sections were rinsed twice for 15 rain sequentially 
with 3%  DMSO in PBS followed by PBS alone,  reflxed twice with 2% 
paraformaldehyde-0.2 % glutaraldehyde for 15 min, dehydrated in ethanol 
(70, 80, 95, and 100%) cleared in xylene, and mounted with Permount 
(Fisher Scientific, Pittsburgh,  PA). 
Embryos were recovered on day 14.5 of  gestation (0.5 corresponds to the 
day the vaginal plug  was observed)  and fixed overnight at 4°C  in 2% 
paraformaldehyde-0.2%  glutaraldehyde  in  PBS. Embryos  were  stained 
with X-gal, processed (to post fixation step) as described above, and pho- 
tographed. 
SubceUular Fractionation 
Organs were rapidly dissected from mice and frozen on dry ice. Transgenic 
animals were identified by incubating a small section of  cervical spinal cord 
in X-gal stain described above. Tissues were homogenized in 0.32 M su- 
close (10% wt/vol), and membrane fractions were obtained by a modifica- 
tion of  the methods of  Whittaker and Barker (1972) and Norton and Poduslo 
(1973). Briefly, homogenates were centrifuged for 11  rain at  1,000 g to 
generate PI and SI. SI was centrifuged at 17,000 g for 60 min to generate 
$2 and 1>2. $2 was centrifuged for 60 min at  100,000 g to generate the 
microsomal fraction and a soluble fraction. P2 was resuspended in 0.32 M 
sucrose and layered ever a discontinuous sucrose gradient containing 12 mi 
1.2 M sucrose and 12 mi 0.88 M sucrose, and centrifuged for 2 h at 53,000 g 
to generate P2A and P2B at the two interfaces and a pellet,  P2C, which 
was resnspended as a mitochondrial  fraction.  P2A and P2B were diluted 
with water and recentrifuged at 75,000 g for 30 min. The resulting P2B pel- 
let was the synaptosomal fraction, and P2A was the myelin fraction. Typi- 
cally  prepared  crude nuclear  preparations  (P1  fraction)  contained  sig- 
nificant myelin contamination  (data not shown). Nuclei for these studies 
were therefore prepared by centrifugation of the original 0.32 M sucrose 
brain homogenate through sucrose gradients containing 0.88, 1.2, and 1.8 M 
sucrose for 5 h. The resulting pellet was the nuclear fraction. 
Samples were assayed for ~-galactosidase activity by the method of Lira 
and Chae (1989). Samples were incubated with 3.5 mM o-nitrophenyl-/~-D- 
galactopyranoside  (ONPG; Sigma Immunochemicals,  St. Louis, MO), in 
PBS containing 0.5 % NP-40 for 30 rain at 37°C. Enzyme activity was mea- 
sured as absorbance at 420 am. 
Northern Blot Analysis 
Total RNA was isolated according to the procedure of Chomczynski and 
Sacchi  (1987) of which  20  /~g  was  fractionated  on 0.68 M  formalde- 
hyde-l.0% agarose gels and transferred to nitrocellulose filters in 20x SSC. 
Random primed probes were used to detect sequentially: LacZ (Sphl-NotI 
fragment  from pGALAK described above),  PLP (EcoRI  fragment  from 
pKK1.38;  Macklin  et  al.,  1991), and pCHOB  (BamHI  fragment  from 
pCHOB;  Harpold  et al.,  1979) transcripts. 
Cell Culture and Immunohistochemistry 
Primary mixed glial cultures (line 26H) were established according to Ed- 
mond et al. (1987). Briefly, cerebral hemispheres were dissected from neo- 
natal mice (3 d old), freed of meninges, and mechanically dissociated in 
Ham's F-12/DME 1:1 (Irvine Scientific, Santa Ana, CA) containing 6 g/liter 
glucose and 10% FBS. The dissociated cells were plated onto 12-mm poly- 
L-lysine-coated glass coverslips in 24-well plates or directly in poly-L-lysine 
coated 6-well plates. Growth medium was changed every 3 d. After  the indi- 
cated days in culture,  ceils were rinsed twice in PBS without Ca  2+ and 
Mg  2+, and fixed for 1 h at room temperature with 4% paraformaldehyde 
in PBS, pH 7.3. Cells were washed twice with PBS and stored at 4°C in 
PBS until use. The cells were permcabilized with 0.1% Triton X-100 in TBS 
(50 mM Tris, 150 mM NaC1, pH 7.4) for 10 rain, rinsed with PBS and in- 
cubated in 5% normal goat serum in TBS for 1-2 h at room temperature. 
Galactosylceramide mAb (GC; Ranseht et al., 1982) was a kind gift from 
Joyce Benjamins  (Wayne State  University, Detroit,  MI)  and polyclonal 
~-galactosidase  antibody  was purchased  from Organon  Teknika-Cappel 
(Durham, NC). Appropriate antibody dilutions were made in 5% goat se- 
rum in TBS, added to the fixed, permeabilized cells and incubated for 1 h 
at room temperature. After 4 rinses with PBS, cells were incubated for 1 h 
at room temperature with fluorescein-isothiocyanate- or rhodamine-conju- 
gated,  species-specific secondary antibodies (Boehringer-Mannheim Bio- 
chemicals, Indianapolis, IN). After staining, coverslips were mounted with 
vinol mounting medium. 
Results 
PLP-LacZ Transgenic Mice 
We developed a transgenic mouse model to study the spatial 
and temporal regulation of PLP gene expression in particu- 
lar, and to serve as a useful marker of oligodendrocytes in 
general. The transgene was generated from two overlapping 
genomic lambda clones, KK1 and 9a (Fig. 1 A). An ApaI site 
in exon 2 was converted to a SphI site with synthetic linkers, 
thereby  transforming  the 5' ApaI site to a unique site. The 
transgene contained 2.4 kb of 5'-flanking PLP DNA, all of 
exon 1 and intron 1, and the first 37 bp of exon 2 fused in 
frame to the LacZ gene. Therefore, the 5'- and 3'-splice sites 
of intron 1 were maintained for correct splicing, and the fu- 
sion protein contained the initiating methionine and the first 
13 amino acids of PLP in addition to/3-galactosidase se- 
quences. The transgene (ApaI-NotI fragment) was purified 
away from vector sequences and microinjected into fertilized 
mouse eggs;  41  pups  were born,  and  34  survived to be 
screened.  These mice were screened for the presence of 
LacZ sequences by Southern blot analysis of genomic DNA 
obtained from tail biopsies.  Three founder mice bearing 
multiple copies of the PLP-LacZ construct were identified, 
and lines 20, 26, and 27 were established from these animals 
(Fig.  1 B).  One of the lines, line 26, was characterized in 
greatest detail.  Founder 26 was chimeric in her germline, 
and her transgenic progeny contained either a  high copy 
number (Fig. 1 B, lane 26H) or low copy number (lane 26L) 
of the transgene (Fig. 1 B). The diversity in line 26 probably 
arose from a partial internal detection of  multiple head to tail 
insertions of the transgene at a single chromosomal locus in 
the founder (data not shown). The two sublines have been 
maintained  stably for over a  year without any detectable 
change in transgene copy number suggesting that the inser- 
tion site was not at a recombinational "hot" spot. All three 
lines expressed the transgene based upon X-gal staining. The 
expression of the transgene in either subline of 26 or in line 
27 was generally at a consistently high level, as determined 
by histological assay.  Thus, lines 26H,  26L, and 27 were 
characterized further. Since line 20 expressed the transgene 
to a lower extent, it was not characterized in detail, although 
line 20 did express the transgene in a tissue-specific manner 
(see below). 
PLP-LacZ Transgene Expression Is Tissue Specific 
The tissue specificity of transgene expression was studied by 
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genic mice.  (A) Structure  of 
the  mouse  PLP  gene  and 
the PLP-LacZ transgene.  The 
relevant  structure  of  the 
mouse  PLP  gene  including 
2.4 kb of the 5' upstream re- 
gion  and  the  entire  exon- 
intron area is illustrated  at the 
top.  The  gene  structure  is 
presented  in a 5' to 3' orienta- 
tion,  with  exons  represented 
by black boxes.  Overlapping 
lambda genomic clones, KK1 
and 9a,  were used to recon- 
strnct PLP intron 1 and gener- 
ate the transgene shown at the 
bottom  of  the  figure.  The 
transgene encompassed PLP sequences  starting with a 5' end 2.4 kb upstream from the cap site and proceeding downstream to the ApaI 
site in exon 2. The ApaI site in exon 2 was mutated to a SphI site, thus making the 5' Apal site unique in the transgene.  The PLP sequences 
were fused in frame to a LacZ expression  cassette (see Materials  and Methods section for details).  The ApaI-NotI fragment was purified 
away from vector sequences  (indicated by wavy lines) and microinjected into fertilized mouse eggs to produce transgenic  mice. Restriction 
sites are indicated as follows: ApaI, A; BamI-II, B; mutated ApaI site, A"'Sph; NotI, N. (B) Southern blot analysis of  genomic DNA isolated 
from PLP-LacZ transgenic  lines.  Genomic DNA (10 #g) was digested  with BamI-II, fractionated  on 0.7% agarose gels,  transferred  to 
nitrocellulose,  hybridized to 32p randomly primed fragments prepared from the LacZ region (SphI-Notl) shown in (A). The autoradio- 
gram shown on the left compares results obtained from lines 20, 27, and 26H while the autoradiogram on the right contrasts the two sublines 
originating  from founder animal 26. 
analyzing LacZ mRNA levels and B-galactosidase enzyme 
activity. Total RNA was isolated from the liver, lung, heart, 
kidney,  spleen,  spinal cord, and brain of a  21-d-old mouse 
from line  26H.  PLP-LacZ and  PLP transcripts  were  de- 
tected  only in the  spinal  cord and brain  (Fig.  2).  Similar 
results  were  obtained  for  enzyme  activity,  using  tissue 
homogenates made from transgenic (26L and 27) and non- 
transgenic mice. B-galactosidase activity was present at de- 
tectable levels only in the brains and spinal cords of trans- 
genie mice (Fig.  3).  Enzyme activity was below the limits 
of detection in sciatic nerve, heart, liver, lung, spleen,  kid- 
ney, or testes.  However, when intact sciatic nerve from all 
three transgenic lines was incubated in X-gal buffer, B-galac- 
tosidase  activity could be detected  (data not shown).  The 
length of time required for development of the blue reaction 
product was consistent with the known levels of transgene 
expression in these animals, i.e., sciatic nerve from lines 26 
and 27 generated blue reaction product within a few hours, 
while sciatic nerve from line 20 required overnight incuba- 
tion and nontransgenic sciatic nerve remained white. When 
sciatic nerve homogenates were analyzed by Western blot, 
sciatic nerve samples  from lines 26 and 27 had detectable 
Figure 2. Northern blot analy-  1.4- 
sis of  mRNA expression in tis- 
sues.  Total RNA was isolated  1.2- 
from the indicated tissues of a 
21-d-old  transgenic  mouse  •  1.o- 
(line  26H).  20 #g was  frac-  ~  .a- 
tionated  by  electrophoresis  ca 
through a denaturing formal-  o  .6- 
dehyde agarose gel (1%) and 
transferred  to a nitrocellulose  .4- 
filter. The blot was probed se-  .2- 
quentially  for  LacZ,  PLP, 
and CHOB transcripts.  RNA  0 
loading was consistent among 
lanes,  as  judged  by  CHOB 
mRNA, which is encoded by 
a  constitutively  expressed 
gene (data not shown). Shown 
are  the  resulting  autoradio- 
grams  for  (A)  PLP  mRNA; 
19-h  exposure  and  (B)  PLP-LacZ mRNA;  9<1  exposure.  The 
PLP-LacZ mRNA is  slightly  longer than the 3.2-kb mRNA for 
PLP. S.C., spinal  cord. 
[]  26 
[]  27 
F  7-~  r--~  ~  7-~  r--~  r--~  .... 
brain  spinal  sciatic  heart  liver  lung  spleen kidney testes 
cord  nerve  I 
Figure 3.  Spatial pattern of B-galactosidase  activity.  Tissues  were 
isolated  from adult transgenic  mice (Line 26L and 27).  Homoge- 
nates were prepared in PBS, and samples  were incubated  with 3.5 
mM ONPG, 0.5%  NP-40 in PBS (Lira and Chae,  1989). Samples 
were 20/xg of brain and spinal cord protein from line 26H, 5 t~g 
of brain and spinal cord protein from line 27 and 100 #g protein 
from other tissues.  Samples were incubated for 2 h and optical den- 
sity was measured at 420 nm. 
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 /~-galactosidase  bands, which were present at significantly 
lower levels than those from brain or spinal cord; heart sam- 
pies  had  no  detectable  /~-gaiactosidase  band  (data  not 
shown). No immunoreactive B-galactosidase band was seen 
in sciatic nerve from line 20,  but this was not unexpected 
since the amount of immunoreactive B-galactosidase in the 
brain and spinal cord of  line 20 mice was extremely low. The 
inability to detect/3-gaiactosidase activity in sciatic nerve 
from any transgenic line in our enzyme assay or on Western 
blots of sciatic nerve from line 20 presumably reflects the ex- 
tremely low level of the protein that is expressed in this tis- 
sue. The selective expression of the transgene in brain, spi- 
nal cord, and at low levels in sciatic nerve indicates that the 
transgene contained the PLP genomic sequences necessary 
to direct tissue specific expression. 
Expression of the PLP-LacZ Transgene Is 
Developmentally Regulated 
Examination of 20-30-#m brain sections stained with X-gal 
revealed that transgene expression (as measured by/3-galac- 
tosidase activity) increased with age and that staining ap- 
peared to localize to white matter areas within the brain (Fig. 
4). Similar developmental patterns were seen for line 27 and 
both sublines of line 26. While abundant blue staining was 
apparent in the transgenic animals, no staining was observed 
in the brains and spinal cords of nontransgenic littermates 
(data not shown)./~-galactosidase activity was evident in the 
brains of mice (line 26H) at postnatal day 5 and increased 
significantly  up to day 21 generally following a caudal to ros- 
tral gradient (Fig. 4). By day 5, transgene expression was de- 
tected in the regions of the olfactory tract, hindbrain, and 
faintly in the midbrain. Stain was first observed in the white 
matter tracts of the cerebellum at day 7  and rapidly in- 
creased, reaching saturating levels by day 21. Enzyme activ- 
ity was detected in the diencephalon by day 8  and in the 
corpus callosum by day 12. Thus, transgene expression was 
regulated temporally and followed a caudal to rostral pat- 
tern,  consistent with normal myelination. B-galactosidase 
activity in line 26L,  which contained substantially lower 
copies of the transgene, showed temporal regulation as well, 
albeit to a  slightly lower level than line 26H in younger 
animals (data not shown). 
Northern blot analysis was performed to evaluate the tem- 
poral expression of transgenic PLP-LacZ and endogenous 
PLP mRNAs in the brains of  mice from line 26L. Total RNA 
isolated from the brains of mice ages 2-28 d exhibited a de- 
velopmental increase in PLP-LacZ mRNA (Fig. 5 B). The 
largest change in PLP-LacZ mRNA levels occurred between 
9 and 12 d. Correspondingly, the three major size classes of 
mRNAs generated from the mouse PLP gene (3.2, 2.4, and 
1.6  kb)  are  regulated  developmentally  and  showed  the 
greatest increase between 9 and 12 d (Fig. 5 A; the autora- 
diogram was overexposed in order to detect the 3.2-kb tran- 
script in 2-d-old brain).  The levels of PLP-LacZ mRNA 
were comparatively less than the PLP mRNAs at all times 
examined, except perhaps in the 2-d brain sample. Interest- 
ingly, the slope of the increase in PLP-LacZ mRNA levels 
was not as great as that for endogenous PLP transcripts. 
The Transgene Is Expressed in 
Cultured Oligodendrocytes 
To assess the cell type responsible for transgene expression, 
blue-stained regions from the brain were examined under 
high magnification (100×).  Cells  demonstrating B-gaiac- 
Figure 5. Northern blot analy- 
sis of developmental mRNA 
expression  in  brain.  Total 
RNA was isolated from brains 
of transgenic mice (line 26L) 
at the indicated ages (postna- 
tal  days 2  through 28)  and 
processed as described in Fig. 
2.  The blot  was probed se- 
quentially  for  LacZ,  PLP, 
and CHOB transcripts. RNA 
loading was consistent among 
lanes  as  determined  by  hy- 
bridization  with  the  CHOB 
probe  (data  not  shown). 
Shown are the  resulting au- 
toradiograms  for  (A)  PLP 
mRNA;  19-h exposure and 
(B)  PLP-LacZ  mRNA; 4-d 
exposure. 
Figure  6.  Morphology  of  transgene expressing cells. High 
magnification (100  x  objective) of Bluo-gal-stained cells from 
brains of transgenic mice at the indicated ages. Staining showed 
cells with bipolar and stellate morphologies at the younger ages 
with a progression to highly arborized cells and white matter tracts 
staining by postnatal day 12. 
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~-galactosidase  (f3-Gal) and GC Expressing  Cells in 
Primary Brain  Cultures 
Days in culture  B-Gal-positive cells  GC-positive cells  /~-Gal/GC 
% 
9  8  11  72 
14  28  34  82 
22  66  73  90 
28  30  33  90 
Mixed primary glial cultures were prepared from neonatal transgenic brains 
(line 26H). Cells were fixed and double stained for B-galactosidase  (a-Gal) and 
GC immunoreactivity. Three fields (200x) were examined at each time point 
and quantified for B-Gal and GC immunoreactivity. Shown are the total  num- 
ber of immunoreacdve cells from the three fields as well as the percentage of 
GC-positive cells that were also positive for/3-Gal. B-Gal positive cells were 
always positive for GC immunoreactivity. 
tosidase activity were morphologically consistent with oli- 
godendroglial development. Bipolar and steUate cells were 
observed at the younger ages with a progression to highly ar- 
borized cells and white matter tracts staining at the older 
ages (Fig. 6). To identify these cells positively as oligoden- 
drocytes, primary mixed glial cultures were prepared from 
neonatal transgenic mouse brains and immunocytochemi- 
cally  evaluated  for  the  oligodendroglial-specific marker, 
galactosylceramide (GC). When quantified for the number 
of GC and/~-galactosidase immunoreactive cells, it was clear 
that at all ages studied,/3-galactosidase was present only in 
cells that were also GC positive (Table I). Thus, the trans- 
gene was not expressed in astrocytes or microglia in these 
cultures. In addition, as cultures matured, an increasing per- 
centage of GC-positive cells became/3-galactosidase positive, 
until by 22-28  d  in culture, 90%  of the GC-positive cells 
were/3-galactosidase positive. 
The Transgene Is Expressed in Embryos 
To evaluate PLP-LacZ expression during embryonic devel- 
opment, a male heterozygous for the transgene (line 26H) 
was bred to a  nontransgenic female, and  14.5-d embryos 
were analyzed for/~-galactosidase activity. X-gal  staining 
was observed throughout the dorsal root ganglia and in the 
olfactory bulb in transgenic embryos at embryonic day 14.5 
(Fig.  7).  Significant staining of most PNS  tracts was ob- 
served also. In fact, more PNS staining was observed than 
CNS staining. No staining was evident in nontransgenic lit- 
termates. 
The Fusion Protein Is Targeted to the Myelin 
The subcellular localization of the transgene product was 
studied  by  EM  and  subcellular  fractionation.  Electron 
micrographs of Bluo-gal-stained tissue suggested that the 
enzyme activity was localized in the compact myelin (Mack- 
lin et al.,  1993).  To confirm this, brain homogenates were 
fractionated and assayed for ~-galactosidase activity. Dra- 
matically higher levels of enzyme activity were detected in 
the myelin fraction prepared  from transgenic brains  than 
other tissues (Fig. 8). Thus, the nuclear, synaptosomal, mi- 
tochondrial,  microsomal,  and  supernatant fractions from 
transgenic brains showed very little/3-galactosidase activity. 
The small amount of activity in the synaptosomal fraction 
Figure 7. Transgene expression in 14.5-d embryos. Whole fetuses 
were stained for/3-galactosidase activity with X-gal. Staining is 
evident in the dorsal root ganglia and the olfactory bulb of trans- 
genie embryos but not in nontransgenic littermates. 
was probably from myelin contamination, since this fraction 
contained PLP, as determined by Western blots (data not 
shown). Essentially no activity was found in fractions ob- 
tained from nontransgenic brains. The enrichment of activ- 
ity in myelin was found for all three transgenic lines, al- 
though the level of activity in myelin from line 20 was quite 
low. These data demonstrate that the first 13 amino acids of 
PLP were sufficient  to target the fusion protein to the myelin, 
and generally to  no other  subcellular  fraction,  including 
cytosol. 
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Figure 8.  /3-galactosidase  activity in subcellular brain fractions. 
fl-galactosidase  activity was measured by incubating samples in 3.5 
mM ONPG for 30 rain and measuring absorbance at 420 nm. Sam- 
ples, lines 26H and 27, 25 #g; line 20, 200 #g. 
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The mechanisms that control oligodendrocyte  differentiation 
in the developing nervous system have a major impact on 
many aspects of brain development. Oligodendrocytes are 
among the most abundant cells in the nervous system, and 
if their differentiation program is disrupted, many areas of 
the CNS are'peramnently impaired. These cells have a very 
well defined differentiation program,  which can be inves- 
tigated extensively in situ and in culture. Because they repre- 
sent a  relatively homogeneous cell population, which ex- 
presses a  small set of myelin-specific genes, and because 
their differentiation program can proceed in culture in the 
absence of other cells and trophic factors, these cells are 
ideally suited for studies designed to understand lineage and 
the control of differentiation in the CNS. In fact, they have 
become an important model for investigating many of these 
quesU.'ons.  The  current  studies  focus  on  one  of  these 
oligodendrocyte-specific genes;  they investigate what  re- 
gions of the PLP gene are important for tissue-specific ex- 
pression, and how its expression is controlled in the develop- 
ing nervous system. 
The presence of  positive or negative tissue-specific regula- 
tory elements within introns has been demonstrated for a va- 
riety  of  genes  including  immunoglobulin  heavy  chain 
(Banerji et al.,  1983;  Gillies et al.,  1983)  and light chain 
genes (Queen and Baltimore,  1983;  Picard and Schaffner, 
1984; Pierce et al., 1991), collagen genes (Bornstein et al., 
1987; Horton et al., 1987; Burbelo et al., 1991), and genes 
encoding  adenosine  deaminase  (Aronow  et  al.,  1989), 
~-globin (Magram et al., 1989),  Thy-1 (Vidal et al., 1990), 
apolipoprotein B (Brooks et al., 1991), glial fibriUary acidic 
protein (Sarker and Cowan, 1991), p53 (Lozano and Levin, 
1991), and PDGF-B (Franklin et al., 1991). We hypothesized 
that  the  mouse  PLP  gene  might  contain  tissue-specific 
regulatory element(s) within the first intron since (a) the 
transfection results analyzing PLP promoter elements did 
not define unambiguously a tissue-specific element within 
the 5'-flanking DNA (Ikenaka et al., 1990; Nave and Lemke, 
1991; Berndt et al., 1992; Cook et al., 1992); (b) the topol- 
ogy of the PLP gene is highly conserved evolutionarily; and 
(c) almost half of the PLP gene is contained within the first 
intron. A transgenic approach was used to test this hypothe- 
sis.  In  these  studies,  the transgene consisted of PLP se- 
quences encompassing 2.4 kb of 5'-flanking DNA,  all of 
exon 1 and intron 1, and the first 37 bp of exon 2 fused in 
frame to a LacZ expression cassette (Fig. 1 A). It should be 
noted that the presence of introns has been shown to increase 
the expression of transgenes in mice (Brinster et ai., 1988; 
Choi et al., 1991; Palmiter et al., 1991). Thus, the inclusion 
of the first intron in our transgene may have been important 
from a  nonspecific and/or technical perspective for trans- 
gene  expression,  and  not  because  of specific  enhancers 
within the intron. While our PLP-LacZ fusion gene did not 
specifically map tissue-specific regulatory element(s) of the 
PLP gene, the transgene appears to contain such elements, 
and we are generating additional transgenic lines with dele- 
tions in the first intron to test our hypothesis that such ele- 
ments reside there. 
The fusion gene contained sequence(s) sufficient  to permit 
spatial and temporal regulation of the transgene in a manner 
similar to  endogenous CNS  PLP gene expression.  PLP- 
LacZ and endogenous PLP/DM-20 transcripts were detected 
in the spinal cord and brain of a 21-d-old mouse (line 26H), 
and not in liver, lung, heart, kidney, nor spleen (Fig. 2). Par- 
allel results were obtained when tissue homogenates were as- 
sayed for/3-gaiactosidase activity (Fig.  3).  One potential 
difference exists between expression of the transgene and the 
normal PLP gene. Recently, DM-20 mRNA has been found 
in the heart (Campagnoni et ai., 1992).  We were unable to 
detect  any /3-galactosidase  activity in  heart homogenates 
prepared from adult transgenic mice (Fig. 3).  Perhaps the 
enzymatic activity was diluted to undetectable levels by non- 
expressing constituents in these tissues, or possibly expres- 
sion is reduced developmentally in the adult. Campagnoni 
et al. (1992) estimated that the level of PLP/DM-20 mRNA 
in the heart was ,,o0.1-0.2% of that in the brain. Conceivably 
our Northern blot analysis was below detection limits, since 
total  RNA  instead  of  poly(A)  ÷  RNA  was  used  in  our 
studies. However, since we were also unable to detect enzy- 
matic activity or/3-galactosidase protein in Western blots 
of heart samples, it is possible that the PLP genomic se- 
quences necessary for mature myocardial expression are ab- 
sent from the fusion gene and reside elsewhere in the PLP 
gene. 
The PLP gene is expressed at a low level in Schwann ceils 
(Puckett et ai.,  1987; Griffiths et al.,  1989;  Stahl et al., 
1990;  Agrawal  and Agrawal,  1991; Gupta  et  al.,  1991; 
Pham-Dinh et ai.,  1991; Ikeneka et al.,  1992;  Kamholz et 
al., 1992; Timsit et al., 1992a).  5-galactosidase was present 
in sciatic nerves prepared from adult mice in all three trans- 
genic lines. The enzyme activity was below the levels of de- 
tection with our enzyme assay, but other techniques demon- 
strated  its  presence.  It  is  possible  that  the  protein  was 
undetectable in the enzyme assay because of its extremely 
low level. The Western blots suggest that the level of the pro- 
tein in sciatic nerve is 2-5 % that in brain. On the other hand, 
it is also possible that the inability to detect it in the enzyme 
assays results from lower enzyme stability in sciatic nerve 
than in brain. This possibility is suggested by the fact that 
intact sciatic nerve stained well with X-gal, and the length 
of time needed for the staining was not dramatically longer 
than that needed for intact spinal cord from the same trans- 
genic line. While X-gal staining is not an accurate quantita- 
tive measure of enzyme activity, it is dependent upon the 
amount of enzyme present, and both spinal cords and sciatic 
nerves from lines 26 and 27 reacted histochemically much 
more rapidly than did spinal cords and sciatic nerves from 
line 20. Thus, it was somewhat surprising that no enzyme ac- 
tivity could be detected in sciatic nerve homogenates in the 
ONPG enzyme assay, since spinal cord and brain homoge- 
nates had measureable enzyme activities in this assay. Per- 
haps the/~-galactosidase enzyme in sciatic nerve is more la- 
bile than the CNS/~-galactosidase, which could be protected 
from denaturation by localization to the myelin membrane. 
It is unclear at present where the/~-galactosidase protein is 
localized in sciatic nerve, but it has been reported that the 
PLP/DM-20 protein in Schwann cells is not present in PNS 
myelin, but is in the cell body (Puckett et al., 1987).  Thus, 
the #-galactosidase activity could be more stable in myelin 
than in the soma. 
Transgene expression was quite extensive in embryonic 
PNS, as well as in discrete regions of the embryonic brain, 
which received direct PNS input. As shown in Fig. 7, the 
The Journal of Cell Biology, Volume  123, 1993  450 dorsal root ganglia and olfactory bulb stained intensively 
with X-gal in embryos at gestational day 14.5. As well, blue 
tracts were evident in the limbs, even extending out into the 
digits of some embryos. This may be correlated to endoge- 
nous DM-20  expression since DM-20  mRNA expression 
precedes that of PLP and appears to predominate in the em- 
bryo (Pham-Dinh et al., 1991; Ikenaka et al., 1992;  Timsit 
et al., 1992a). What cell type in either the embryonic CNS 
or PNS is expressing the transgene and what the function of 
a PLP gene product is in these embryos are intriguing and 
important questions. Does DM-20 act in embryonic cells of 
the glial lineage to control some aspect of their differentia- 
tion? How does this protein, which appears to function in 
myelin as a hydrophobic structural protein in a multilarnellar 
membrane, function in embryos, which have no such mul- 
tilamellar membranes?  These  questions  are  being  inves- 
tigated with our transgenic lines. 
The PLP-LacZ fusion gene also contained the necessary 
PLP genomic sequences to direct temporal expression of the 
transgene.  Developmental regulation of transgene expres- 
sion exists for LacZ mRNA as shown by Northern analysis 
(Fig. 5). A substantial increase occurred between 9 and 12 d 
for both PLP-LacZ and endogenous PLP transcripts.  The 
levels oftransgene mRNA were less than those for PLP/DM- 
20 mRNAs at all ages studied. Similar results were obtained 
with a  MBP-LacZ transgene (Gow et al.,  1992).  Interest- 
ingly,  the  slope  of the  increase  of PLP-LacZ transgene 
mRNA levels during development was quite different from 
that of the endogenous PLP mRNA. The PLP-LacZ mRNA 
increase appeared to be relatively consistent throughout de- 
velopment, while the PLP mRNA increase was more dra- 
matic between 9 and 12 d. In other studies, we have demon- 
strated that the transcription rate of the PLP gene increases 
during development by several fold (Macklin et al.,  1991). 
Since PLP mRNA levels rise by orders of magnitude during 
development, the transcription rate cannot be solely respon- 
sible for the increase in mRNA levels, which suggests that 
another level of  PLP gene regulation must exist postranscrip- 
tionally. Other studies investigating the mechanisms control- 
ling PLP gene expression have suggested that protein kinase 
C activity may control some aspect of PLP mRNA stability 
in  differentiating oligodendrocytes (Asotra  and  Macklin, 
1993).  This mRNA stability could be controlled by second- 
ary structure within the >2,000 bases of the 3'-noncoding 
segment of the PLP/DM-20 mRNAs. Since this segment is 
not present in the PLP-LacZ fusion transcript,  transgene 
mRNAS would not be controlled in the same manner. On the 
other hand, that region of the PLP mRNA was included in 
the transgene expressed by Gow et al. (1992),  and it did not 
appear to stabilize LacZ transcripts to any great extent. 
The transgene was expressed in primary mixed glial cul- 
tures derived from neonatal brains.  Immunocytochemical 
analysis showed the/3-galactosidase activity was found only 
in putative oligodendrocytes, i.e.,  all /3-galactosidase  im- 
munoreactive cells  were  immunoreactive also  for GC,  a 
marker for immature as well as mature oligodendrocytes (Ta- 
ble I). These data imply that oligodendrocyte progenitors do 
not express the transgene, since GC appears only in imma- 
ture and mature oligodendrocytes, not in progenitors, which 
express A2B5 prior to GC (Raft et al., 1983).  However,  low 
levels of transgene expression probably would be below the 
levels of detection by immunocytochemistry. As cells ma- 
tured in the mixed culture, and presumably begin to express 
more PLP, the number of B-galactosidase positive cells in- 
creased, as did the percentage of GC positive cells that were 
/3-galactosidase positive. The subpopulation of oligodendro- 
cytes that did not express the PLP-LacZ fusion gene at de- 
tectable levels was reduced with time in culture, and in older 
cells only 10% of GC positive cells did not appear to express 
B-galactosidase. 
Since the immunoreactivity for B-galactosidase colocal- 
ized with that for PLP, subcellular localization of the fusion 
protein was investigated. Intriguingly, the transgene product 
was localized in the myelin membrane itself as determined 
by EM and subcellular fractionation of brain homogenates 
(Fig. 8). Thus it appears that the first 13 amino acids of PLP 
are sufficient to target the protein to myelin. Whether target- 
ing to the myelin sheath is the result of an active process or 
a passive event, such as association of the short PLP peptide 
with the endogenous PLP/DM-20 proteins remains to be de- 
termined. It is noteworthy that, although PLP/DM-20 tran- 
scripts are translated on bound ribosomes (Colman et al., 
1982), the microsomal fraction did not contain any B-galac- 
tosidase activity,  suggesting that this  chimeric protein is 
localized primarily in the sheath and is not retained in the 
endoplasmic reticulum. This is intriguing in that when DM- 
20 cDNA is transfected into HeLa cells, the protein accumu- 
lates predominantly in vesicles, presumably ER and Golgi, 
although some DM-20 protein moves to the plasma mem- 
brane (Timsit et al., 1992b).  Thus, a more complete move- 
ment to the myelin membrane is effected  with our PLP-LacZ 
fusion protein in situ, which does not accumulate in vesicles. 
This suggests that some cell-specific or developmental fac- 
tors are important for the movement of these proteins within 
oligodendrocytes. 
These data on the localization of the PLP-LacZ fusion 
protein are extremely important since they imply that a very 
small segment of this protein is sufficient to target it ap- 
propriately.  Related  data  have  been  presented  for  cyto- 
chrome b5, where the carboxy-terminal 10 amino acids ap- 
pear sufficient to target the protein to the ER (Mitoma and 
Ito,  1992),  and  for  growth-associated protein  (GAP-43) 
where the NH2-terminal 10 amino acids have been reported 
to target reporter proteins to the growth cone in transfected 
cells (Zuber et al., 1989), although other reports about trans- 
fection of GAP-43 reporter constructs do not agree with the 
initial observation (Liu et al.,  1991). Similarly, the first 12 
amino acids (less than half of the presequence) of an im- 
ported mitochondrial protein could direct mouse cytosolic 
dihydrofolate reductase into the yeast mitochondrial matrix 
(Hurt et al., 1985). It should be noted that not all transgenic 
products in oligodendrocytes will target to the myelin mem- 
brane. For example, Gow et al. (1992) did not find B-galac- 
tosidase in the myelin membrane in their MBP-LacZ mice. 
A search of the current data bases for sequence homology 
to the NH2-terminal 13 amino acids of PLP did not reveal 
any significant identity to other proteins.  However,  iden- 
tification of targeting sequences solely by sequence analysis 
is often times insufficient. For instance, many random se- 
quences  can  functionally replace the  secretion signal  se- 
quence of yeast invertase for targeting to the plasma mem- 
brane  (Kaiser  et  al.,  1987).  Nonetheless,  several  of the 
amino acids in the NH2-terminal portion of PLP warrant 
further discussion. Myristoylation of NH2-terminal glycine 
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shown to be important in targeting  proteins (Pellman et al., 
1985).  Although PLP is acylated and it contains an NH2- 
terminal glycine, the NH2 terminus is not blocked and the 
predominant fatty acid is palmitic acid (Lees and Bizzozero, 
1992).  Recently,  it  has  been  shown  that  PLP  cysteine 
residues at positions 5, 6, 9,  108,  138, and 140 are modified 
by long-chain fatty acids (Weimb and Stoffel,  1992).  Thus, 
acylation of the first three cysteine residues may be important 
in targeting our fusion protein. On the other hand, PLP acy- 
lation has been shown to occur within the myelin membrane 
itself (Lees and Bizzozero,  1992),  suggesting that covalent 
lipid modifications may not be important for targeting  this 
protein. A di-leucine motif has been implicated in lysosomal 
targeting  of T cell antigen receptor chains (Letourneur and 
Klausner,  1992), but our results did not indicate targeting of 
the  fusion  protein  to  the  lysosome  even  though  leucine 
residues are found in positions two and three of PLP. 
The observation that the NH2-terminal  13 amino acids of 
PLP were sufficient to target the fusion protein to the myelin 
membrane does not preclude the possibility that  multiple 
recognition determinants  may exist within the protein. The 
human low density lipoprotein receptor was recently shown 
to  contain  two  different  determinants  that  independently 
mediated  sorting  to  the  basolateral  plasma  membrane  in 
MDCK cells (Matter et al., 1992). Additionally,  targeting of 
multimeric proteins may require specific interactions of the 
subunits,  and some multimeric proteins that fail to assemble 
correctly are not transported  to their proper location.  The 
NH2-terminai  domains  of acetylcholine  receptor  subunits 
have been shown to contain recognition signals for the initial 
steps of receptor assembly (Verrall and Hall,  1992).  It has 
been postulated that the PLP aggregates  to form channels 
within the myelin membrane (Lees and Bizzozero,  1992). 
Thus,  targeting  of our fusion protein to the myelin mem- 
brane could be explained if the NH2-terminal  region of PLP 
was important in PLP aggregation. 
The  presence  of/3-galactosidase,  which  is  a  relatively 
large protein (,o120 kD), in the myelin membrane has had 
no discernible effect on the function or stability of the myelin 
in these animals.  Heterozygous adult mice (6-9 mo) from 
several lines and homozygous adult mice from line 26 have 
no obvious  clinical  signs  of dysmyelination,  and electron 
micrographs of adult tissue indicate no dramatic  alteration 
in the appearance of compact myelin. Nevertheless, the pres- 
ence of the enzyme in the myelin membrane alters it at some 
level,  since staining of the membrane for enzyme activity 
disrupts  compact  myelin  extensively  (data  not  shown). 
Studies are under way to localize the enzyme more discretely 
within the myelin sheath. 
The  current  studies  have  demonstrated  that  PLP-LacZ 
transgene expression is an excellent measure ofPLP gene ex- 
pression in embryos and postnatal animals, as well as in pri- 
mary cultured oligodendrocytes. These cells are now tagged 
with  LacZ with no  apparent  detrimental  effect,  and they 
should be ideal for transplantation  studies. Further investiga- 
tions into the consequences of targeting  a new protein into 
the myelin membrane itself may provide important new in- 
sights into myelination and dysmyelination. 
The authors thank Dr. Robin Fisher, Director of the Neurohistology Core 
of the UCLA Mental Retardation Research Center for extensive consulta- 
tion on the neuroanatomical aspects of transgene expression; Dr. Karl Her- 
rup for discussions  on use of LacZ; Janet Miyashiro, Kristine Engelbrecht, 
Lee Zane, and Svetlana Arutyunovna  for excellent technical assistance; and 
Carol Gray and Sharon Belkin for assistance with the artwork. We thank 
Dr.  Leroy Hood for his encouragement and support. 
These studies were supported by grants from the National Multiple Scle- 
rosis  Society  and  National  Institutes  of  Health  grants  NS25304  and 
HD25831 to W. B. Macklln and AG07687 (C. Readhead). P. A. Wight 
was  supported  by  a  fellowship  from the National  Institutes of Health 
(NS08774) and C. S. Duchala by a fellowship from the National Multiple 
Sclerosis Society. 
Received for publication 19 March 1993 and in revised form 1 July 1993. 
References 
Agrawal, H. C., and D. Agrawal. 1991.  Proteolipid protein and DM-20 are 
synthesized  by Schwann cell, present in myelin membrane, but they are not 
fatty acylated. Neurochem.  Res.  16:855-858. 
Aronow, B., D. Lattier, R. Silbiger, M. I)nsing, J. Hutton, G. Jones, J. Stock, 
J.  McNeish, S. Potter,  D. Wive, and D. Wiginton. 1989.  Evidence for a 
complex  regulatory  array  in  the  first  intron  of the  human adenosine 
deaminase gone. Genes & Dev.  3:1384-1400. 
Asotra, K., and W. B. Macklin. 1993. Protein kinase C activity modulates my- 
elin gone expression in enriched oligodendrocytes. J.  Neurosci.  Res.  34: 
571-588. 
Baaerji, T. L., L. Olson, and W. Schaffnor.  1983. A lymphocyte specific en- 
hancer is located downstream  of the  joining region of immunoglobulin  heavy 
chain genes. Cell. 33:729-740. 
Bern&, J.  A., J.  (3.  Kim, and L.  D.  Hudson.  1992.  Identification  of cis- 
regulatory dements in the myelin proteolipid protein (PLP) gone. J. Biol. 
Chem. 267:14730-14737. 
Bornstein, P., J. McKay, J. K. Morishima, S. Devarayalu, and R. E. Gelinas. 
1987.  Regulatory elements in the first intron cona'ibute to transcriptional 
control of the human ctl  (I) collagen geue. Proc.  Natl. Acad.  Sci. USA. 
84:8869-8873. 
Brinster,  R.  L.,  J.  M.  Allen, R.  R.  Behringor, R.  E.  Gelinas, and R.  D. 
Palmiter.  1988.  Introns increase transcriptional efficiency  in  transgenic 
mice. Proc. Natl. Acad.  Sci. USA. 85:836-840. 
Brooks, A. R., B. D. Blackhart, K. Hanbold, and B. Levy-Wilson. 1991. Char- 
acterization of tissue-specific enhancer elements in the second intron of the 
human apolipoprotein  B gone. J. Biol. Chem. 266:7848-7859. 
Burbelo, P.  D., L. A. Broggoman, G. C.  Gabriel,  P. E.  Klotman, and Y. 
Yamada. 1991. Characterization ofa eis-acting element required for efficient 
transcriptional activation of the collagen IV enhancer. J. Biol. Chem. 266: 
22297-22302. 
Campagnoni, A. T. 1988. Molecular biology of myelin proteins from the cen- 
tral nervous system. J. Neurochem.  51:1-14. 
Campagnoni, A. T., and W. B. Macklin. 1988. Cellular and molecular aspects 
of myelin protein gone expression. Mol. Neurobiol.  2:41-89. 
Campagnoni, C. W., B. Garbay, P. Micevych, T. Pribyl, K. Kampf, V. W. 
Handley, and A. T. Campagnoni. 1992.  DM-20 mRNA splice product of 
the myelin proteolipid protein gone is expressed in the murine heart. J. Neu- 
rosci. Res.  33:148-155. 
Choi, T., M. Huang, C. Gorman, and R. Jaenisch. 1991. A generic intron in- 
creases gone expression in transgenic mice. Mol. Cell. Biol. 11:3070-3074. 
Chomczynski, P., and N. Sacchi.  1987. Single-step method of RNA isolation 
by acid guanidinium thiocyanate-phonol-chloroform extraction. Anal. Bio- 
chem.  162:156-159. 
Colman, D. R., G. Kreibich, A. B. Frey, and D. D. Sabatini.  1982. Synthesis 
and incorporation of myelin polypeptides into CNS myelin. J.  Cell Biol. 
95:598-608. 
Cook, J. L., S. Irias-Donaghey, and P. L. Deininger. 1992. Regulation of ro- 
dent myelin proteolipid protein gone expression. Neurosci. Lett. 137:56-60. 
Diehl, H.-J., M. Schaich, R.-M. Budzinski, and W. Stoffel.  1986.  Individual 
exons encode the integral membrane domains of human myelin proteolipid 
protein. Proc. Natl. Acad $ci. USA. 83:9807-9811. 
Dubois-Dalcq, M., T. Behar, L. Hudson, and R. A. Lazzarini. 1986.  Emer- 
gence of  three myelin proteins in oligodendrocytes cultured without neurons. 
J.  Cell Biol. 102:384-392. 
Edmond, J., R. A. Robbins, J. D. Bergstrom, R. A. Cole, and J. de Vellis. 
1987. Capacity of substrate utilization in oxidative metabolism by neurons, 
astrocytes and oligodendrocytes from developing brain in primary culture. 
J.  Neurosci. Res.  18:551-561. 
Eng, L. F., F. C. Chao, B. Gersti, D. Pratt, and M. G. Tavastsjerna. 1968. 
The maturation of human white matter myelin: fractionation of the myelin 
membrane proteins. Biochemistry.  7:4455-4465. 
Franklin,  G.  C.,  M.  Donovan, G.  I.  R.  Adam, L.  Hulmgren, S.  Pfeifer- 
Ohisson, and R. Ohisson. 1991.  Expression of the human PDGF-B geue is 
regulated by both positively and negatively acting cell type-specific  regula- 
tory elements located in the first intron. EMBO (Fur. Mol. Biol. Organ.) J. 
10:1365-1373. 
The Journal of Cell Biology, Volume 123,  1993  452 Gardinier, M. V., and W. B. Macklin. 1988.  Myelin proteolipid protein gene 
expression in jimpy and jimpy  ~a mice. J.  Neurochem.  51:360-369. 
Gardinier, M. V., W. B. Macklin, A. J. Diniak, and P. L. Deininger. 1986. 
Characterization of myelin proteolipid mRNAs in normal and jimpy mice. 
Mol.  Cell. Biol. 6:3755-3762. 
Gillies, S., S. Morrison, V. Oi, and S. Tonegawa. 1983. A tissue-specific  tran- 
scription enhancer is located in the major intron of a rearranged immuno- 
globulin heavy chain gene. Cell. 33:717-728. 
Gow, A., V. L. Friedrich, Jr., and R. A. Lazzarini. 1992. Myelin basic protein 
gene contains separate enhancers for oligodendrocyte and Schwann cell ex- 
pression. J.  Cell Biol. 119:605-616. 
Grittiths, I. R., L. S. Mitchell, K. McPhilemy, S. Morrison, E. Kyriakides, 
and J. A. Barrie. 1989. Expression of myelin protein genes in Schwann  cells. 
J.  Neurocytol.  18:345-352. 
Gupta, S. K., J. Pringle, J. F. Poduslo, and C. Mezei.  1991.  Levels of pro- 
teolipid  protein mRNAs in peripheral nerve are not under stringent axonal 
control. J.  Neurochem.  56:1754-1762. 
Harpold, M. M., R. M. Evans, M. Salditt-Georgieff,  and J. E. Darnell. 1979. 
Production of mRNA in Chinese hamster cells: Relationship of the rate of 
synthesis  to the cytoplasmic concentration of nine specific mRNA sequences. 
Cell.  17:1025-1035. 
Hogan, B. L., F. Costantini, and E. Lacy. 1986.  Manipulation of the Mouse 
Embryo: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold 
Spring Harbor, NY. 332 pp. 
Horton, W., T. Miyashita, K. Kohno, J. R. Hassell, and Y. Yamada.  1987. 
Identification  of a phenotype-specific enhancer in the first intron of the rat 
collagen II gene. Proc.  Natl. Acad.  Sci. USA. 84:8864-8868. 
Hurt, E. C., B. Pesold-Hurt, K. Suda, W. Oppliger, and G. Schatz. 1985. The 
first twelve amino acids (less than half of the pre-sequence) of an imported 
mitocbondrial protein can direct mouse cytosolic dihydrofolate reductase 
into the yeast mitochondrial matrix. EMBO (Fur. Mol. Biol. Organ.)  J. 
4:2061-2068. 
Huxley, A. F., and R. Staempfli.  1949.  Evidence for saltatory conduction in 
peripheral myelinated nerve fibres. J.  Physiol.  108:315-339. 
Ikenaka, K., T. Furuichi, Y. lwasaki, A. Moriguchi, and H. Okano. 1988. My- 
elin proteolipid protein gene structure and its regulation of expression in nor- 
mai and jimpy mutant mice. J.  Mol. Biol. 199:587-596. 
Ikenaka, K., I. Fujino, N. Morita, Y. lwasaki, M. Miura, T. Kagawa, K. Naka- 
hira,  and K.  Mikoshiba.  1990.  Reliable transiem promoter assay using 
fiuorescein-di-~-D-galactopyranoside  substrate. DNA Cell Biol. 9:279-286. 
Ikenaka, K., H. Ohano, T.-A. Tamura, and K. Mikoshiba. 1991.  Recent ad- 
vances in  studies on genes for myelin proteins.  Dev.  Growth  & Differ. 
33:181-192. 
Ikenaka, K., T. Kagawa, and K. Mikoshiba. 1992. Selective expression of DM- 
20, an alternatively spliced myelin proteolipid protein gene product, in de- 
veloping  nervous  system  and  in  nonglial  cells.  J.  Neurochem.  58: 
2248-2253. 
Kaiser, C. A., D. Preuss, P. Grisafi, and D. Botstein. 1987. Many random se- 
quences functionally replace the secretion signal sequence of yeast invertase 
for targeting to the plasma membrane. Science  (Wash. DC). 235:312-317. 
Kamholz, K., M. Sessa, S. Scherer, H. Volgelbacker, K. Mokuno, P. Baron, 
L. Wrabetz, M. Shy, and D. Pleasure.  1992.  Structure and expression of 
proteolipid protein in the peripheral nervous system. J. Neurosci. Res.  31 : 
23 !-244. 
Kronquist, K. E.,  B. F. Crandall, W. B. Macldin, and A. T. Campaguoni. 
1987.  Expression of myelin proteins in the developing human spinal cord: 
cloning and sequencing of human proteolipid protein cDNA. J.  Neurosci. 
Res.  18:395-401. 
Lees, M. B., and O. A. Bizzozero.  1992. Structure and acylation of proteolipid 
protein. In Myelin: Biology and Chemistry. R. E. Martenson, editor. CRC 
Press, Inc., Boca Raton, FL. 237-255. 
Letourneur, F.,  and R.  D.  Klansner.  1992.  A novel di-leucine motif and a 
tyrosine-based  motif independently mediate lysosomal targeting and endocy- 
tosis of CD3 chains. Cell. 69:1143-1157. 
LeVine, S. M., D. Wong, and W. B. Macklin. 1990. Developmental expression 
of proteolipid protein and DM-20 mRNAs and proteins in the rat brain. Dev. 
Neurasci.  12:235-250. 
Lira, K., and C.-B. Chae. 1989. A simple assay for DNA transfection by incu- 
bation of the cells in culture dishes with substrates for beta-galactosidase. 
Biotechniques.  7:576-579. 
Liu, Y., E. R. Chapman, and D. R. Storm. 1991.  Targeting of neuromodulin 
(GAP-43) fusion  proteins to growth cones in cultured rat embryonic neurons. 
Neuron.  6:411-420. 
Lt~wy, A. D., P. C. Bridgman, and T. C. Mettenleiter. 1991./5-gaiactosidase 
expressing recombinant pseudorabies virus for light and electron micro- 
scopic  study of transneuronally labeled CNS  neurons. Brain  Res.  555: 
346-352. 
Lozano, G., and A. J. Levine. 1991. Tissue-specific  expression of p53 in trans- 
genie mice is regulated by intron sequences. Mol. Carcinog. 4:3-9. 
Macklin, W. B., C. W. Campaguoni, P. L. Deininger, and M. V. Gardinier. 
1987. Structure and expression of  the mouse  myelin proteolipid protein gene. 
J.  Neurosci.  Res.  18:383-394. 
Macklin, W. B., M. W. Gardinier, Z. O. Obeso, K. D. King, and P. A. Wight. 
1991. Mutations in the myelin proteolipid protein gene alter oligodendrocyte 
gene expression in jimpy and jirapy ~  mice. J.  Neurochem.  56:163-171. 
Macklin, W. B., P. A. Wight, C. Duchala, and C. Readhead. 1993. Transgenic 
models for investigating oligodendrocyte differentiation  and myelin forma- 
tion, In A Multidisciplinary Approach to Myelin. Plenum Press, New York. 
In press. 
Magram, J., K. Niederreither, and F. Costantini. 1989. #-globin enhancers tar- 
get expression of a heteroiogous gene to erythroid tissues of transgenic mice. 
Mol.  Cell. Biol. 9:4581-4584. 
Mattei, M. G., P. M. Alliel, A. Dautigny, E. Passage, D. Pham-Dinh, J. F. 
Mattei, and P. Jolles.  1986,  The gene encoding for the major brain pro- 
teolipid  (PIP) maps on the q-22 band of the human X chromosome. Hum. 
Genet. 72:352-353. 
Matter, K., W. Hunziker, and I. Mellman. 1992.  Basolateral sorting of LDL 
receptor in MDCK cells: the cytoplasmic domain contains two tyrosine- 
dependent targeting determinants. Cell. 71:741-753. 
Mikoshiba, K., H. Okano, T. Tamura, and K. Ikenaka.  1991.  Structure and 
function of myelin protein genes. Annu.  Rev. Neurasci.  14:201-217. 
Milner, R. J., C. Lai, K.-A. Nave, D. Lenior, J. Ogata, and J. G. Sutclifte. 
1985. Nucleotide sequences of two mRNAs for rat brain myelin proteolipid 
protein.  Cell. 42:931-939. 
Mitoma,  J.,  and  A.  Ito.  1992.  The  carboxy-terminal  10  amino  acids  of 
cytochrome b5 are necessary for its targeting to the endoplasmic reticulum. 
EMBO  (Eur. Mol.  Biol. Organ.) J.  11:4197-4203. 
Nave, K.-A., and G. Lemke. 1991. Induction of the myelin proteolipid protein 
(PLP) gene in C6 glioblastoma cells: functional analysis of the PLP pro- 
rooter.  J.  Neurosci.  11:3060-3069. 
Nave, K.-A., C. Lai, F. E. Bloom, and R. J. Milner. 1987. Splice site selection 
in the proteolipid protein (PLP) gene transcript and primary structure of the 
DM-20 protein of CNS myelin. Proc. Natl. Acad. Sci. USA. 84:5666-5669. 
Norton, W. T., and S. E. Poduslo. 1973. Myelination in rat brain: changes in 
myelin composition during brain maturation. J.  Neurochem.  21:759-773. 
Palmiter, R. D., E. P. Sandgren, M. R. Avarbock, D. D. Allen, and R. L. Brin- 
ster.  1991.  Heteroiogous introns can enhance expression of transgenes in 
mice. Proc. Natl. Acad.  Sci. USA. 88:478-482. 
Pellman, D., E. A. Garber, F. R. Cross, and H. Hanafusa. 1985. An N-terminal 
peptide from p60src can direct myristoylation and plasma membrane local- 
ization when fused to heterologous proteins. Nature (Lond.). 314:374-397. 
Pham-Dinh, D., M.-C. Biding, G. Roussel, A. Dantiguy, and J.-L. Nussbanm. 
1991.  Proteolipid  DM-20 predominates over PLP in PNS.  Neuroreport. 
2: 89-92. 
Picard,  D., and W. Schaffner,  1984.  A lymphocyte-specific enhancer in the 
mouse immunoglobulin k gene. Nature  (Lond.) 307:80-82. 
Pierce, J. W., A. M. Gifford, and D. Baltimore. 1991. Silencing of the expres- 
sion of the immunoglobulin kappa gene in non-B cells. Mol. Cell. Biol. 
11:1431-1437. 
Puckett, C., L. Hudson, K. Ono, V. Friedrich, J. Benecke, M. Dubois-Dalcq, 
and R. A. Lazzarini. 1987. Myelin-specific proteolipid protein is expressed 
in myelinating Schwann cells but is not incorporated into myelin sheaths. J. 
Neurasci.  Res.  18:511-518. 
Queen, C., and D. Baltimore. 1983. Immunoglobulin  gene transcription is acti- 
vated by downstream sequence elements. Cell. 33:741-748. 
Raft, M. C., R. H. Miller, and M. Noble.  1983.  A glial progenitor cell that 
develops in vitro into an astrocyte or an oligodendrocyte depending on the 
culture medium. Nature  (Lond.).  303:390-396. 
Raine, C.  S.  1984.  Morphology of myelin and myelination. ]n  Myelin. P. 
Morell, editor.  Plenum Press, New York.  1-50. 
Ranscht, B., P. A. Clapshaw, J. Price, M. Noble, and W. Seifert.  1982. The 
development of oligodendrocytes and Schwann cells studied with a monoclo- 
hal antibody against gaiactocerebroside. Proc.  Natl. Acad.  Sci. USA. 79: 
2709-2713. 
Readhead, C., B. Popko, N. Takahashi, H. D. Shine, R. A. Saavedra, R. L. 
Sigman, and L. Hood. 1987.  Expression of a myelin basic protein gene in 
transgenic shiverer mice: correction of the dysmyelinating  phenotype. Cell. 
48:703-712. 
Sanes, J. R., J. L. R. Rubanstein, and J.-F. Nicolas. 1986. Use of  a recombinant 
retrovirus to study post-implantation cell lineage in mouse embryos. EMBO 
(Fur. Mol. Biol. Organ.)J.  5:3133-3142. 
Sarkar, S., and N. J. Cowan. 1991. Intragenic sequences affect the expression 
of the gene encoding glial  fibrillary  acidic  protein.  J.  Neurochem.  57: 
675-684. 
Schindler, P., B. Luu, O. Sorokine, T. Trifilieff, and A. Van Dorsselaer. 1990. 
Developmental study of proteolipids in bovine brain: a novel proteolipid and 
DM-20 appear before proteolipid protein during myelination. J. Neurochem. 
55:2079-2085. 
Simons, R., N. Alon, and J. R. Riordan.  1987.  Human myelin DM-20 pro- 
teolipid protein deletion defined by eDNA sequence. Biochem. Biophys. Res. 
Commun.  146:666-671. 
Stahl, N., J. Harry, and B. Popko. 1990. Quantitative analysis of myelin protein 
gene expression during development in the rat sciatic nerve. Mol. Brain Res. 
8:209-212. 
Timsit, S.  G.,  L.  BaUy-Cuif, D.  R.  Colman, and B.  Zalc.  1992a.  DM-20 
mRNA is expressed during the embryonic development of the nervous sys- 
tem of the mouse. J.  Neurochem.  58:1172-1175. 
Timsit, S., M. P. Sinoway, L. Levy, B. Allinquant, J. Stempak, S. M. Staugai- 
tis, and D. R. Colman. 1992b. The DM-20 protein of myelin: Intracellular 
and surface expression patterns in transfectants. J.  Neurochem.  58:1936- 
Wight et al. Proteolipid Protein-LacZ  Transgene Expression and Targeting  453 1942. 
Verrall, S., and Z. W. Hall.  1992.  The N-terminal domains of acetyicholine 
receptor subunits contain recognition signals for the initial steps of receptor 
assembly. Cell.  68:23-31. 
Vidal, M., R. Morris, F. Grosveld, and E. Spanopoulou. 1990. Tissue-specific 
control elements of the Thy-1 gene. EMBO (Eur.  Mol.  Biol.  Organ.) J. 
9:833-840. 
Weimbs, T., and W. Stoffel.  1992.  Proteolipid  protein (PLP) of CNS myelin: 
positions of free, disulfide-bonded, and fatty acid thioester-linked cysteine 
residues and implications for membrane topology of PLP. Biochemistry. 
31 : 12289-12296. 
Whittaker, V. P., and L. A. Barkar. 1972. The subcellular fractionation of  brain 
tissue with special reference to the preparation of synaptosomes and their 
component  organelles. In Methods of Neurochemistry, vol. 2. R. Fried, edi- 
tor. Marcel Dekkar, New York.  1-52. 
Willard, H. F., and J. R. Riordan.  1985.  Assignment of the gene for myelin 
proteolipid protein to the X chromosome: implications for X-linked myelin 
disorders. Science (Wash.  DC). 230:940-942. 
Zuber, M. X., S. M. Strittmatter, and M. C. Fishman. 1989.  A membrane- 
targeting signal in the amino terminus of the neuronal protein GAP-43. Na- 
ture (Lond.).  341:345-348. 
The Journal of Cell Biology, Volume 123,  1993  454 